We use cookies to improve your browsing experience and provide meaningful content. Read our cookie policy. Accept
  •  Customer Login
  • Register
  •  View Cart (0)
  •  Customer Login
  • Register
  •  View Cart (0)

Takara Bio
  • Products
  • Services & Support
  • Learning centers
  • APPLICATIONS
  • About
  • Contact Us

Clontech Takara Cellartis

Close

  • ‹ Back to Technotes
  • Enabling long-read RNA sequencing from low-input samples
  • Singular for low input total RNA seq
  • All-in-one cDNA synthesis and library prep from single cells
  • Automation-friendly, all-in-one cDNA synthesis and library prep
  • All-in-one cDNA synthesis and library prep from ultra-low RNA inputs
  • 3' mRNA libraries from single cells (SMART-Seq v4 3' DE Kit)
  • Full-length mRNA-seq for target capture
  • Stranded libraries from single cells
  • Stranded libraries from picogram-input total RNA (v3)
  • Stranded libraries from 100 pg-100 ng total RNA
  • Stranded libraries from 100 ng - 1 ug total RNA
  • Stranded libraries from FFPE inputs (v2)
  • Nonstranded libraries from FFPE inputs
  • Singular and Takara Bio library prep
  • Full-length, single-cell, and ultra-low-input RNA-seq with UMIs
Learn more about our pico-input SMARTer RNA-seq products. SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian
Home › Learning centers › Next-generation sequencing › RNA-seq › Technotes › Stranded libraries from picogram-input total RNA (v3)

RNA-seq

  • Automated library prep
  • Technologies and applications
    • SMART technology
    • Single-cell mRNA-seq
    • Total RNA-seq
    • SMART-Seq PLUS solutions
  • Technotes
    • Enabling long-read RNA sequencing from low-input samples
    • Singular for low input total RNA seq
    • All-in-one cDNA synthesis and library prep from single cells
    • Automation-friendly, all-in-one cDNA synthesis and library prep
    • All-in-one cDNA synthesis and library prep from ultra-low RNA inputs
    • 3' mRNA libraries from single cells (SMART-Seq v4 3' DE Kit)
    • Full-length mRNA-seq for target capture
    • Stranded libraries from single cells
    • Stranded libraries from picogram-input total RNA (v3)
    • Stranded libraries from 100 pg-100 ng total RNA
    • Stranded libraries from 100 ng - 1 ug total RNA
    • Stranded libraries from FFPE inputs (v2)
    • Nonstranded libraries from FFPE inputs
    • Singular and Takara Bio library prep
    • Full-length, single-cell, and ultra-low-input RNA-seq with UMIs
  • Webinars
    • Pushing the limits of sensitivity for single-cell applications
    • Capturing biological complexity by high-resolution single-cell genomics
    • Taking single-cell RNA-seq by STORM
    • STORM-seq Q&A
    • Neural multiomics Q&A
    • Liver metabolic function, dissecting one cell at a time
    • Pushing the limits Q&A
    • Total RNA sequencing of liquid biopsies
    • Liver metabolic function Q&A
    • Automating full-length single-cell RNA-seq libraries
    • Single-cell whole transcriptome analysis
    • Sensitivity and scale for neuron multiomics
  • RNA-seq tips
  • RNA-seq FAQs
New products
Need help?
Contact Sales
Learn more about our pico-input SMARTer RNA-seq products. SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian
Tech Note

Generate UMI-labeled, stranded libraries for whole-transcriptome analyses, compatible with Illumina NGS platforms.

  • Unique molecular identifiers for downstream data analysis
    Seamless integration of UMIs in the protocol help to mitigate PCR bias and accurately identify true variants and rare mutations, without any additional deduplication steps.
  • Superior sequencing performance
    Reconfigured sequencing libraries perform well on all Illumina® platforms without the addition of PhiX adapter-ligated library as a control.
Introduction Results Conclusions Methods References

Introduction  

Massively parallel cDNA sequencing, or RNA-seq, has become the gold standard for whole-transcriptome gene expression analysis and is widely used in numerous applications to study cell and tissue transcriptomes. However, despite its many advantages, RNA-seq can be challenging in some situations, including cases where input amounts are low or comprised of degraded RNA samples.

Takara Bio was a pioneer in the development of a low-input solution: RiboGone technology for rRNA removal from total RNA, which enables library construction from inputs spanning 10 ng to 100 ng. We integrated this technology into our SMARTer stranded RNA-seq kits, reducing the representation of rRNA in the final libraries and leading to exceptional performance with inputs as low as 10 ng. With the release of the SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian, we were able to be successful with even lower inputs by incorporating ZapR™, a proprietary technology in which ribosomal cDNA is removed after creating the complete cDNA library, thereby enriching RNAs of interest—namely mRNA and non-polyadenylated RNA. 

The latest update to the original kit, the SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian (referred to as “Pico v3," see workflow in Figure 1) now features the inclusion of unique molecular identifiers (UMIs). UMIs not only help mitigate PCR bias but also provide the user with the opportunity to identify true variance within the sample. Pico v3 provides a unique, sensitive, and ligation-free method to generate stranded, Illumina-ready cDNA libraries from an input range of 250 pg–10 ng of total mammalian RNA in about 7.5 hours.

Schematic of technology in the SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian

Figure 1. Schematic of technology in the SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian. SMART technology is used in this ligation-free protocol to preserve strand-of-origin information. Random priming (represented by the green N6 Primer) allows the generation of cDNA from all RNA fragments in the sample, including rRNA. When the SMARTScribe™ II Reverse Transcriptase (RT) reaches the 5ʹ end of the RNA fragment, the enzyme’s terminal transferase activity adds a few nontemplated nucleotides to the 3ʹ end of the cDNA (shown as XXXXX). The Pico v3 SMART UMI Adapter (included in the SMART UMI-TSO Mix v3) base-pairs with the nontemplated nucleotide stretch, creating an extended template to enable the RT to continue replicating to the end of the oligonucleotide. The Pico v3 SMART UMI Adapter also contains 8 random nucleotides which function as the unique molecular identifiers for downstream data analysis. In the next step, the first round of PCR amplification (PCR 1) adds full-length Illumina adapters, including barcodes. The 5ʹ PCR Primer binds to the Pico v3 SMART UMI Adapter sequence (light purple), while the 3ʹ PCR Primer binds to the sequence associated with the random primer (green). The ribosomal cDNA is then cleaved by ZapR v3 in the presence of the mammalian-specific R-Probes. The resulting cDNA contains sequences derived from the random primer and the Pico v3 SMART UMI Adapter used in the reverse transcription reaction. This process leaves the library fragments originating from non-rRNA molecules untouched, with priming sites available on both 5ʹ and 3ʹ ends for further PCR amplification. These fragments are enriched via a second round of PCR amplification (PCR 2) using primers universal to all libraries. The final library contains sequences that allow clustering on any Illumina flow cell (see details in Figure 2).

Results  

Unique molecular identifiers for downstream data analysis

Commonly used high-throughput sequencing platforms, including the Illumina NextSeq®, require PCR amplification during library construction to increase the number of cDNA molecules to an amount sufficient for sequencing and/or enrichment for fragments with successful adapter ligation (Cha and Thilly 1998; Dohm et al. 2008). However, PCR often stochastically introduces errors, such as sequencing artifacts and false mutations, that can propagate to late cycles. Biases in the PCR amplification step lead to particular sequences becoming overrepresented in the final library, resulting in an inaccurate fold-change measurement (Aird et al. 2011). What then, is the solution? This is where UMIs come in.

Unique molecular identifiers (UMIs) are molecular tags that are used to detect and quantify unique mRNA transcripts. The random sequence composition of UMIs assures that every fragment-UMI combination is unique in the library—much like how a barcode identifies an item in a grocery store or the Dewey decimal system identifies a book in a library. By using UMIs ligated to fragments of the input sample, PCR clones can be found by searching for non-unique fragment-UMI combinations, and therefore help to determine whether a sequence arises from truly distinct molecules, or from PCR amplification (Fu et al. 2018). UMIs provide the highest level of error correction and accuracy, allowing for superior representation of the transcripts.

UMIs are incorporated into all libraries produced with Pico v3 without additional steps required (Figure 2). An 8-nt UMI is introduced into the same location in each fragment during library preparation through the reverse transcription step (prior to PCR amplification). Thus, it is possible to accurately identify PCR duplicates and correct for specific preferentially amplified sequences. High-resolution reads and accurate detection of true variants are now achievable.

Figure 2. Structural features of final libraries generated with the SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian. The adapters added using the SMARTer RNA Unique Dual Index Kit - 24U (Cat. # 634451) contain sequences allowing clustering on any Illumina flow cell (P7 shown in light blue, P5 shown in red, Index 1 [i7] sequence shown in orange, and Index 2 [i5] sequence shown in yellow), as well as the regions recognized by sequencing primers Read Primer 2 (Read 2, purple) and Read Primer 1 (Read 1, green). Read 1 generates sequences antisense to the original RNA, while Read 2 yields sequences sense to the original RNA (orientation of original RNA denoted by 5ʹ and 3ʹ in dark blue). The first 8 nt of the second sequencing read (Read 2) are UMIs (dark purple) followed by 3 nucleotides of UMI-linker (shown as NNN) and 3 nucleotides derived from the Pico v3 SMART UMI Adapter (shown as XXX).

Superior sequencing performance 

To test the consistency in the performance of Pico v3 over the recommended input range, libraries were generated from human lung cancer normal adjacent tissue (NAT FFPE) from a single donor (500 pg–10 ng), with two technical replicates per input amount (Figure 3).

Sequencing metrics were shown to be consistent between technical replicates, as well across the entire range of RNA input amounts. The average number of transcripts ≥0.1 TPM (transcripts per kilobase million) was reported as 43,778 ± 1,352 (mean ± s.d., standard deviation), CV=3.1%. Similarly, the average number of genes ≥1 TPM was reported as 18,690 ± 276, CV=1.5%. Comparison transcript expression levels also indicated a strong correlation across a range of input amounts. Proportions of reads mapped to various RNA species were comparable, regardless of RNA input amount. Of particular note were the relatively low proportions of reads mapping to nuclear and mitochondrial rRNA compared to those of the remaining RNA species reported.

Although we recommend using high-quality, gDNA-free RNA, we often notice residual levels of gDNA contamination in some challenging RNA samples (e.g., degraded RNA extracted from FFPE), resulting in high intergenic mapping rates and low strand specificities. Therefore, we validated an optional step (see the user manual, Appendix A) to remove potential gDNA contamination from RNA samples if such contamination is shown to be an issue. This optional step is seamlessly integrated into the Pico v3 workflow and significantly improves sequencing performance, as is indicated by a reduced fraction of reads mapped to intergenic RNA and a higher strand specificity versus no treatment (data not shown).

Sequencing alignment metrics from 500 pg–10 ng total RNA
RNA source Human lung cancer total RNA (NAT FFPE)
Input amount (ng) 0.5 1 5 10
Number of reads (millions) 4.0 (paired-end reads)
Discarded reads (%) 5.9 3.6 2.7 2.3 1.2 1.1 4.7 4.3
Unique reads (%) 87 87 92 92 96 95 97 97
Overall mapping (%) 92 94 96 96 97 97 94 94
Number of transcripts  ≥0.1 TPM  41,245 42,293 44,189 44,217 44,814 44,361 44,051 45,067
Number of genes  ≥0.1 TPM 18,193 18,414 18,829 18,680 18,821 18,660 18,941 18,980
Strand specificity 92 92 92 92 92 92 92 92
Proportion of total reads (%)
Exonic 21 22 22 22 21 21 14 21
Intronic 58 59 60 61 63 64 58 60
Intergenic 6.0 6.1 6.2 6.2 6.3 6.3 6.1 6.3
rRNA 5.8 6.4 6.1 6.2 5.5 5.1 8.5 6.6
Mitochondrial 0.9 1.0 1.0 1.0 1.0 0.9 0.9 0.8
Genomic 85 87 89 89 91 91 84 87
Duplicate 13 13 8 8 4 5 3 3

Table 1. Performance metrics for Pico v3. Sequencing libraries were generated from total RNA extracted from human lung FFPE tissue using the Pico v3 kit and sequenced on a MiniSeq™ Sequencing System. Sequencing metrics are shown for libraries generated from inputs of 0.5, 1, 5, and 10 ng, with two technical replicates per input amount. Sequences were analyzed as described in the Methods.

Conclusions  

The SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian is a complete solution to the challenge of creating stranded, indexed cDNA libraries for RNA-seq from picogram amounts of total mammalian RNA. The unique combination of SMART technology with ZapR for ribosomal cDNA depletion enables unparalleled sensitivity, consistency, and reproducibility over the recommended range of 250 pg–10 ng, with demonstrated results from inputs as low as 100 pg. This kit excels with high-quality, partially degraded, and low-quality input RNA, enabling consistent, reproducible results from a broad range of sample types. Additionally, design updates made to this version of the kit allow for seamless integration of unique molecular identifiers (UMIs) into the protocol, helping to mitigate PCR bias and accurately identify true variants and rare mutations within the sample. In around 7.5 hours, using very low total RNA input amounts from samples of varying types and qualities, this kit can generate Illumina-ready libraries that accurately represent coding and noncoding RNA—a major development in library prep for next-gen RNA-seq.

Methods  

Library preparation and sequencing for FFPE samples

To evaluate the performance of the Pico v3 kit with FFPE samples, total RNA was extracted from FFPE human lung cancer normal adjacent tissue (BioOption) using a NucleoSpin total RNA FFPE kit (Cat. # 740982.10). Prior to library preparation, RNA integrity was evaluated on an Agilent Bioanalyzer using an Agilent RNA 6000 Pico Kit (Agilent, Cat. # 5067-1513), yielding a DV200 value of 66%. Libraries were generated from the extracted RNA using the Pico v3 kit without additional RNA fragmentation (Protocol Option 2 in the user manual). Libraries were sequenced on a MiniSeq Sequencing System using a MiniSeq High Output Reagent Kit (150 cycles), (Illumina, Cat. # FC-420-1002). Sequencing reads were aligned to the human transcriptome and the human genome.

Sequencing data analysis

Reads from all libraries were trimmed and mapped to mammalian rRNA and the human mitochondrial genomes using CLC Genomics Workbench. The remaining reads were subsequently mapped to the human genome using CLC with ENSEMBL-GRCh38.81 annotation. All percentages shown, including the number of reads that map to introns, exons, or intergenic regions, are percentages of the total reads in the library. The number of transcripts identified in each library was determined by the number of transcripts with an TPM greater than or equal to 0.1, as shown in Table 1.

References  

Aird, D., Ross, M.G., Chen, W. et al. Analyzing and minimizing PCR amplification bias in Illumina sequencing libraries. Genome Biol. 12:R18 (2011).

Cha R.S. & Thilly W.G. Specificity, efficiency, and fidelity of PCR. PCR Methods Appl. 3:S18–S29 (1993).

Dohm J.C., Lottaz C., Borodina T., Himmelbauer H. Substantial biases in ultra-short read data sets from high-throughput DNA sequencing. Nucleic Acids Res. 36:e105 (2008).

Everaert C., et al. Benchmarking of RNA-sequencing analysis workflows using whole-transcriptome RT-qPCR expression data. Sci Rep. 7:1559 (2017).

Fu, Y., Wu, P., Beane, T. et al. Elimination of PCR duplicates in RNA-seq and small RNA-seq using unique molecular identifiers. BMC Genomics 19:531 (2018).

Mortazavi, A., Williams, B.A., McCue K., Schaeffer L., Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5:621–628 (2008).

Related Products

Cat. # Product Size Price License Quantity Details
634485 SMARTer® Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian 24 Rxns USD $2685.00

License Statement

ID Number  
425 LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
392 This Product is protected by one or more patents from the family consisting of:US10941397, People's Republic of China Patent: ZL201480057094.4, US10781443, US10954510, DE602014069266.4, EP3058104, FR3058104, UK3058104, JP6602294, SE3058104, CA2923812, and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family. Information on relevant patents and licenses for this product may be found at: https://www.takarabio.com/patents. 
395
This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family.  Additional information may be found at https://www.takarabio.com/patents. 
450 This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.
455 This product is sold under license from Becton Dickinson and Co., and may be the subject of U.S. Patent Nos.: 8,835,358; 9,290,809; 9,315,857; 9,708,659; 9,845,502; 10,047,394; 10,059,991; 10,202,646; 10,392,661; 10,619,203; 11,970,737; 12,060,607; and its foreign counterparts.

The SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian is used to generate strand-specific RNA-seq libraries for Illumina sequencing from 250 pg–10 ng inputs of purified total RNA or from 10–1,000 intact cells. This kit incorporates Takara Bio’s proprietary SMART (Switching Mechanism at the 5’ end of RNA Template) technology and includes refinements to the SMARTer method for stranded RNA-seq that simplify the library preparation workflow and improve sequencing performance. This method was developed to work with either high- or low-quality total RNA, does not require additional rRNA removal methods or kits, and produces sequencing libraries that retain strand-of-origin information. The integrated removal of cDNAs derived from rRNA—typically present in high abundance following cDNA synthesis from total RNA inputs—makes the workflow extremely sensitive, yielding data that is highly reproducible with low mapping to rRNA. The new library design featured in this updated kit adds an 8 nucleotide (nt) unique molecular identifier (UMI) through the reverse-transcription step to mitigate potential PCR bias as well as to provide customers with additional information for transcript quantification, specifically for true variants and rare mutations. This kit includes the SMARTer RNA Unique Dual Index Kit - 24U (Takara Bio, Cat. No. 634451). SMARTer RNA Unique Dual Index Kit – 96U Set A and B (Cat. #s 634452, and 634457) are available for purchase. Together they offer up to 192 unique dual indexes for multiplexing.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Documents Components Image Data

Back

634485: SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian

634485: SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian
634486 SMARTer® Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian 48 Rxns USD $4265.00

License Statement

ID Number  
425 LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
392 This Product is protected by one or more patents from the family consisting of:US10941397, People's Republic of China Patent: ZL201480057094.4, US10781443, US10954510, DE602014069266.4, EP3058104, FR3058104, UK3058104, JP6602294, SE3058104, CA2923812, and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family. Information on relevant patents and licenses for this product may be found at: https://www.takarabio.com/patents. 
395
This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family.  Additional information may be found at https://www.takarabio.com/patents. 
450 This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.
455 This product is sold under license from Becton Dickinson and Co., and may be the subject of U.S. Patent Nos.: 8,835,358; 9,290,809; 9,315,857; 9,708,659; 9,845,502; 10,047,394; 10,059,991; 10,202,646; 10,392,661; 10,619,203; 11,970,737; 12,060,607; and its foreign counterparts.

The SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian is used to generate strand-specific RNA-seq libraries for Illumina sequencing from 250 pg–10 ng inputs of purified total RNA or from 10–1,000 intact cells. This kit incorporates Takara Bio’s proprietary SMART (Switching Mechanism at the 5’ end of RNA Template) technology and includes refinements to the SMARTer method for stranded RNA-seq that simplify the library preparation workflow and improve sequencing performance. This method was developed to work with either high- or low-quality total RNA, does not require additional rRNA removal methods or kits, and produces sequencing libraries that retain strand-of-origin information. The integrated removal of cDNAs derived from rRNA—typically present in high abundance following cDNA synthesis from total RNA inputs—makes the workflow extremely sensitive, yielding data that is highly reproducible with low mapping to rRNA. The new library design featured in this updated kit adds an 8 nucleotide (nt) unique molecular identifier (UMI) through the reverse-transcription step to mitigate potential PCR bias as well as to provide customers with additional information for transcript quantification, specifically for true variants and rare mutations. This kit includes the SMARTer RNA Unique Dual Index Kit - 24U (Takara Bio, Cat. No. 634451). SMARTer RNA Unique Dual Index Kit – 96U Set A and B (Cat. #s 634452, and 634457) are available for purchase. Together they offer up to 192 unique dual indexes for multiplexing.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Documents Components Image Data

Back

634486: SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian

634486: SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian
634487 SMARTer® Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian 96 Rxns USD $5504.00

License Statement

ID Number  
425 LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
392 This Product is protected by one or more patents from the family consisting of:US10941397, People's Republic of China Patent: ZL201480057094.4, US10781443, US10954510, DE602014069266.4, EP3058104, FR3058104, UK3058104, JP6602294, SE3058104, CA2923812, and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family. Information on relevant patents and licenses for this product may be found at: https://www.takarabio.com/patents. 
395
This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family.  Additional information may be found at https://www.takarabio.com/patents. 
450 This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.
455 This product is sold under license from Becton Dickinson and Co., and may be the subject of U.S. Patent Nos.: 8,835,358; 9,290,809; 9,315,857; 9,708,659; 9,845,502; 10,047,394; 10,059,991; 10,202,646; 10,392,661; 10,619,203; 11,970,737; 12,060,607; and its foreign counterparts.

The SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian is used to generate strand-specific RNA-seq libraries for Illumina sequencing from 250 pg–10 ng inputs of purified total RNA or from 10–1,000 intact cells. This kit incorporates Takara Bio’s proprietary SMART (Switching Mechanism at the 5’ end of RNA Template) technology and includes refinements to the SMARTer method for stranded RNA-seq that simplify the library preparation workflow and improve sequencing performance. This method was developed to work with either high- or low-quality total RNA, does not require additional rRNA removal methods or kits, and produces sequencing libraries that retain strand-of-origin information. The integrated removal of cDNAs derived from rRNA—typically present in high abundance following cDNA synthesis from total RNA inputs—makes the workflow extremely sensitive, yielding data that is highly reproducible with low mapping to rRNA. The new library design featured in this updated kit adds an 8 nucleotide (nt) unique molecular identifier (UMI) through the reverse-transcription step to mitigate potential PCR bias as well as to provide customers with additional information for transcript quantification, specifically for true variants and rare mutations. This kit includes the SMARTer RNA Unique Dual Index Kit - 24U (Takara Bio, Cat. No. 634451). SMARTer RNA Unique Dual Index Kit – 96U Set A and B (Cat. #s 634452, and 634457) are available for purchase. Together they offer up to 192 unique dual indexes for multiplexing.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Documents Components Image Data

Back

634487: SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian

634487: SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian
634488 SMARTer® Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian 192 Rxns Inquire for Quotation

License Statement

ID Number  
425 LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
392 This Product is protected by one or more patents from the family consisting of:US10941397, People's Republic of China Patent: ZL201480057094.4, US10781443, US10954510, DE602014069266.4, EP3058104, FR3058104, UK3058104, JP6602294, SE3058104, CA2923812, and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family. Information on relevant patents and licenses for this product may be found at: https://www.takarabio.com/patents. 
395
This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family.  Additional information may be found at https://www.takarabio.com/patents. 
450 This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.
455 This product is sold under license from Becton Dickinson and Co., and may be the subject of U.S. Patent Nos.: 8,835,358; 9,290,809; 9,315,857; 9,708,659; 9,845,502; 10,047,394; 10,059,991; 10,202,646; 10,392,661; 10,619,203; 11,970,737; 12,060,607; and its foreign counterparts.
*

The SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian is used to generate strand-specific RNA-seq libraries for Illumina sequencing from 250 pg–10 ng inputs of purified total RNA or from 10–1,000 intact cells. This kit incorporates Takara Bio’s proprietary SMART (Switching Mechanism at the 5’ end of RNA Template) technology and includes refinements to the SMARTer method for stranded RNA-seq that simplify the library preparation workflow and improve sequencing performance. This method was developed to work with either high- or low-quality total RNA, does not require additional rRNA removal methods or kits, and produces sequencing libraries that retain strand-of-origin information. The integrated removal of cDNAs derived from rRNA—typically present in high abundance following cDNA synthesis from total RNA inputs—makes the workflow extremely sensitive, yielding data that is highly reproducible with low mapping to rRNA. The new library design featured in this updated kit adds an 8 nucleotide (nt) unique molecular identifier (UMI) through the reverse-transcription step to mitigate potential PCR bias as well as to provide customers with additional information for transcript quantification, specifically for true variants and rare mutations. This kit includes the SMARTer RNA Unique Dual Index Kit - 24U (Takara Bio, Cat. No. 634451). SMARTer RNA Unique Dual Index Kit – 96U Set A and B (Cat. #s 634452, and 634457) are available for purchase. Together they offer up to 192 unique dual indexes for multiplexing.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Documents Components Image Data

Back

634488: SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian

634488: SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian

*You must be logged in to a Purchasing Account in order to purchase these products online, since the purchase of these products may be restricted depending on your account type. Researchers at not-for-profit accounts receive a limited use license with their purchase of the product. Researchers at for-profit accounts must obtain a license prior to purchase. For details please contact licensing@takarabio.com.

Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2025 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.

Takara Bio

Takara Bio USA, Inc. provides kits, reagents, instruments, and services that help researchers explore questions about gene discovery, regulation, and function. As a member of the Takara Bio Group, Takara Bio USA is part of a company that holds a leadership position in the global market and is committed to improving the human condition through biotechnology. Our mission is to develop high-quality innovative tools and services to accelerate discovery.

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES (EXCEPT AS SPECIFICALLY NOTED).

Support
  • Contact us
  • Technical support
  • Customer service
  • Shipping & delivery
  • Sales
  • Feedback
Products
  • New products
  • Special offers
  • Instrument & reagent services
Learning centers
  • NGS
  • Gene function
  • Stem cell research
  • Protein research
  • PCR
  • Cloning
  • Nucleic acid purification
About
  • Our brands
  • Careers
  • Events
  • Blog
  • Need help?
  • Announcements
  • Quality and compliance
  • That's Good Science!
Facebook Twitter  LinkedIn

logo strip white

©2025 Takara Bio Inc. All Rights Reserved.

Region - North America Privacy Policy Terms and Conditions Terms of Use

Top



  • COVID-19 research
  • Viral detection with qPCR
  • SARS-CoV-2 pseudovirus
  • Human ACE2 stable cell line
  • Viral RNA isolation
  • Viral and host sequencing
  • Vaccine development
  • CRISPR screening
  • Drug discovery
  • Immune profiling
  • Publications
  • Next-generation sequencing
  • Spatial omics
  • RNA-seq
  • DNA-seq
  • Single-cell NGS automation
  • Reproductive health
  • Bioinformatics tools
  • Immune profiling
  • Real-time PCR
  • Great value master mixes
  • Signature enzymes
  • High-throughput real-time PCR solutions
  • Detection assays
  • References, standards, and buffers
  • Stem cell research
  • Media, differentiation kits, and matrices
  • Stem cells and stem cell-derived cells
  • mRNA and cDNA synthesis
  • In vitro transcription
  • cDNA synthesis kits
  • Reverse transcriptases
  • RACE kits
  • Purified cDNA & genomic DNA
  • Purified total RNA and mRNA
  • PCR
  • Most popular polymerases
  • High-yield PCR
  • High-fidelity PCR
  • GC rich PCR
  • PCR master mixes
  • Cloning
  • In-Fusion seamless cloning
  • Competent cells
  • Ligation kits
  • Restriction enzymes
  • Nucleic acid purification
  • Automated platforms
  • Plasmid purification kits
  • Genomic DNA purification kits
  • DNA cleanup kits
  • RNA purification kits
  • Gene function
  • Gene editing
  • Viral transduction
  • Fluorescent proteins
  • T-cell transduction and culture
  • Tet-inducible expression systems
  • Transfection reagents
  • Cell biology assays
  • Protein research
  • Purification products
  • Two-hybrid and one-hybrid systems
  • Mass spectrometry reagents
  • Antibodies and ELISAs
  • Primary antibodies and ELISAs by research area
  • Fluorescent protein antibodies
  • New products
  • Special offers
  • OEM
  • Portfolio
  • Process
  • Facilities
  • Request samples
  • FAQs
  • Instrument services
  • Apollo services
  • ICELL8 services
  • SmartChip ND system services
  • Gene and cell therapy manufacturing services
  • Services
  • Facilities
  • Our process
  • Resources
  • Customer service
  • Sales
  • Make an appointment with your sales rep
  • Shipping & delivery
  • Technical support
  • Feedback
  • Online tools
  • GoStix Plus FAQs
  • Partnering & Licensing
  • Vector information
  • Vector document overview
  • Vector document finder
Takara Bio's award-winning GMP-compliant manufacturing facility in Kusatsu, Shiga, Japan.

Partner with Takara Bio!

Takara Bio is proud to offer GMP-grade manufacturing capabilities at our award-winning facility in Kusatsu, Shiga, Japan.

  • Automation systems
  • Shasta Single Cell System introduction
  • SmartChip Real-Time PCR System introduction
  • ICELL8 introduction
  • Next-generation sequencing
  • RNA-seq
  • Technical notes
  • Technology and application overviews
  • FAQs and tips
  • DNA-seq protocols
  • Bioinformatics resources
  • Webinars
  • Spatial biology
  • Real-time PCR
  • Download qPCR resources
  • Overview
  • Reaction size guidelines
  • Guest webinar: extraction-free SARS-CoV-2 detection
  • Technical notes
  • Nucleic acid purification
  • Nucleic acid extraction webinars
  • Product demonstration videos
  • Product finder
  • Plasmid kit selection guide
  • RNA purification kit finder
  • mRNA and cDNA synthesis
  • mRNA synthesis
  • cDNA synthesis
  • PCR
  • Citations
  • PCR selection guide
  • Technical notes
  • FAQ
  • Cloning
  • Automated In-Fusion Cloning
  • In-Fusion Cloning general information
  • Primer design and other tools
  • In‑Fusion Cloning tips and FAQs
  • Applications and technical notes
  • Stem cell research
  • Overview
  • Protocols
  • Technical notes
  • Gene function
  • Gene editing
  • Viral transduction
  • T-cell transduction and culture
  • Inducible systems
  • Cell biology assays
  • Protein research
  • Capturem technology
  • Antibody immunoprecipitation
  • His-tag purification
  • Other tag purification
  • Expression systems
  • Antibodies and ELISA
  • Molecular diagnostics
  • Interview: adapting to change with Takara Bio
  • Applications
  • Solutions
  • Partnering
  • Contact us
  • mRNA and protein therapeutics
  • Characterizing the viral genome and host response
  • Identifying and cloning protein targets
  • Expressing and purifying protein targets
  • Immunizing mice and optimizing vaccines
  • Pathogen detection
  • Sample prep
  • Detection methods
  • Identification and characterization
  • SARS-CoV-2
  • Antibiotic-resistant bacteria
  • Food crop pathogens
  • Waterborne disease outbreaks
  • Viral-induced cancer
  • Immunotherapy research
  • T-cell therapy
  • Antibody therapeutics
  • T-cell receptor profiling
  • TBI initiatives in cancer therapy
  • Cancer research
  • Kickstart your cancer research with long-read sequencing
  • Sample prep from FFPE tissue
  • Sample prep from plasma
  • Cancer biomarker quantification
  • Single cancer cell analysis
  • Cancer transcriptome analysis
  • Cancer genomics and epigenomics
  • HLA typing in cancer
  • Gene editing for cancer therapy/drug discovery
  • Alzheimer's disease research
  • Antibody engineering
  • Sample prep from FFPE tissue
  • Single-cell sequencing
  • Reproductive health technologies
  • Embgenix FAQs
  • Preimplantation genetic testing
  • ESM partnership program
  • ESM Collection Kit forms
  • Infectious diseases
  • Develop vaccines for HIV
Create a web account with us

Log in to enjoy additional benefits

Want to save this information?

An account with takarabio.com entitles you to extra features such as:

•  Creating and saving shopping carts
•  Keeping a list of your products of interest
•  Saving all of your favorite pages on the site*
•  Accessing restricted content

*Save favorites by clicking the star () in the top right corner of each page while you're logged in.

Create an account to get started

  • BioView blog
  • Automation
  • Cancer research
  • Career spotlights
  • Current events
  • Customer stories
  • Gene editing
  • Research news
  • Single-cell analysis
  • Stem cell research
  • Tips and troubleshooting
  • Women in STEM
  • That's Good Support!
  • About our blog
  • That's Good Science!
  • SMART-Seq Pro Biomarker Discovery Contest
  • DNA extraction educational activity
  • That's Good Science Podcast
  • Season one
  • Season two
  • Season three
  • Our brands
  • Our history
  • In the news
  • Events
  • Biomarker discovery events
  • Calendar
  • Conferences
  • Speak with us
  • Careers
  • Company benefits
  • Trademarks
  • License statements
  • Quality statement
  • HQ-grade reagents
  • International Contacts by Region
  • United States and Canada
  • China
  • Japan
  • Korea
  • Europe
  • India
  • Affiliates & distributors
  • Need help?
  • Privacy request
  • Website FAQs

That's GOOD Science!

What does it take to generate good science? Careful planning, dedicated researchers, and the right tools. At Takara Bio, we thoughtfully develop exceptional products to tackle your most challenging research problems, and have an expert team of technical support professionals to help you along the way, all at superior value.

Explore what makes good science possible

 Customer Login
 View Cart (0)
Takara Bio
  • Home
  • Products
  • Services & Support
  • Learning centers
  • APPLICATIONS
  • About
  • Contact Us
  •  Customer Login
  • Register
  •  View Cart (0)

Takara Bio USA, Inc. provides kits, reagents, instruments, and services that help researchers explore questions about gene discovery, regulation, and function. As a member of the Takara Bio Group, Takara Bio USA is part of a company that holds a leadership position in the global market and is committed to improving the human condition through biotechnology. Our mission is to develop high-quality innovative tools and services to accelerate discovery.

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES (EXCEPT AS SPECIFICALLY NOTED).

Clontech, TaKaRa, cellartis

  • Products
  • COVID-19 research
  • Next-generation sequencing
  • Real-time PCR
  • Stem cell research
  • mRNA and cDNA synthesis
  • PCR
  • Cloning
  • Nucleic acid purification
  • Gene function
  • Protein research
  • Antibodies and ELISA
  • New products
  • Special offers
  • COVID-19 research
  • Viral detection with qPCR
  • SARS-CoV-2 pseudovirus
  • Human ACE2 stable cell line
  • Viral RNA isolation
  • Viral and host sequencing
  • Vaccine development
  • CRISPR screening
  • Drug discovery
  • Immune profiling
  • Publications
  • Next-generation sequencing
  • Spatial omics
  • RNA-seq
  • DNA-seq
  • Single-cell NGS automation
  • Reproductive health
  • Bioinformatics tools
  • Immune profiling
  • Real-time PCR
  • Great value master mixes
  • Signature enzymes
  • High-throughput real-time PCR solutions
  • Detection assays
  • References, standards, and buffers
  • Stem cell research
  • Media, differentiation kits, and matrices
  • Stem cells and stem cell-derived cells
  • mRNA and cDNA synthesis
  • In vitro transcription
  • cDNA synthesis kits
  • Reverse transcriptases
  • RACE kits
  • Purified cDNA & genomic DNA
  • Purified total RNA and mRNA
  • PCR
  • Most popular polymerases
  • High-yield PCR
  • High-fidelity PCR
  • GC rich PCR
  • PCR master mixes
  • Cloning
  • In-Fusion seamless cloning
  • Competent cells
  • Ligation kits
  • Restriction enzymes
  • Nucleic acid purification
  • Automated platforms
  • Plasmid purification kits
  • Genomic DNA purification kits
  • DNA cleanup kits
  • RNA purification kits
  • Gene function
  • Gene editing
  • Viral transduction
  • Fluorescent proteins
  • T-cell transduction and culture
  • Tet-inducible expression systems
  • Transfection reagents
  • Cell biology assays
  • Protein research
  • Purification products
  • Two-hybrid and one-hybrid systems
  • Mass spectrometry reagents
  • Antibodies and ELISA
  • Primary antibodies and ELISAs by research area
  • Fluorescent protein antibodies
  • Services & Support
  • OEM
  • Instrument services
  • Gene and cell therapy manufacturing
  • Customer service
  • Sales
  • Shipping & delivery
  • Technical support
  • Feedback
  • Online tools
  • Partnering & Licensing
  • Vector information
  • OEM
  • Portfolio
  • Process
  • Facilities
  • Request samples
  • FAQs
  • Instrument services
  • Apollo services
  • ICELL8 services
  • SmartChip ND system services
  • Gene and cell therapy manufacturing
  • Services
  • Facilities
  • Our process
  • Resources
  • Sales
  • Make an appointment with your sales rep
  • Online tools
  • GoStix Plus FAQs
  • Vector information
  • Vector document overview
  • Vector document finder
  • Learning centers
  • Automation systems
  • Next-generation sequencing
  • Spatial biology
  • Real-time PCR
  • Nucleic acid purification
  • mRNA and cDNA synthesis
  • PCR
  • Cloning
  • Stem cell research
  • Gene function
  • Protein research
  • Antibodies and ELISA
  • Automation systems
  • Shasta Single Cell System introduction
  • SmartChip Real-Time PCR System introduction
  • ICELL8 introduction
  • Next-generation sequencing
  • RNA-seq
  • Technical notes
  • Technology and application overviews
  • FAQs and tips
  • DNA-seq protocols
  • Bioinformatics resources
  • Webinars
  • Real-time PCR
  • Download qPCR resources
  • Overview
  • Reaction size guidelines
  • Guest webinar: extraction-free SARS-CoV-2 detection
  • Technical notes
  • Nucleic acid purification
  • Nucleic acid extraction webinars
  • Product demonstration videos
  • Product finder
  • Plasmid kit selection guide
  • RNA purification kit finder
  • mRNA and cDNA synthesis
  • mRNA synthesis
  • cDNA synthesis
  • PCR
  • Citations
  • PCR selection guide
  • Technical notes
  • FAQ
  • Cloning
  • Automated In-Fusion Cloning
  • In-Fusion Cloning general information
  • Primer design and other tools
  • In‑Fusion Cloning tips and FAQs
  • Applications and technical notes
  • Stem cell research
  • Overview
  • Protocols
  • Technical notes
  • Gene function
  • Gene editing
  • Viral transduction
  • T-cell transduction and culture
  • Inducible systems
  • Cell biology assays
  • Protein research
  • Capturem technology
  • Antibody immunoprecipitation
  • His-tag purification
  • Other tag purification
  • Expression systems
  • APPLICATIONS
  • Molecular diagnostics
  • mRNA and protein therapeutics
  • Pathogen detection
  • Immunotherapy research
  • Cancer research
  • Alzheimer's disease research
  • Reproductive health technologies
  • Infectious diseases
  • Molecular diagnostics
  • Interview: adapting to change with Takara Bio
  • Applications
  • Solutions
  • Partnering
  • Contact us
  • mRNA and protein therapeutics
  • Characterizing the viral genome and host response
  • Identifying and cloning protein targets
  • Expressing and purifying protein targets
  • Immunizing mice and optimizing vaccines
  • Pathogen detection
  • Sample prep
  • Detection methods
  • Identification and characterization
  • SARS-CoV-2
  • Antibiotic-resistant bacteria
  • Food crop pathogens
  • Waterborne disease outbreaks
  • Viral-induced cancer
  • Immunotherapy research
  • T-cell therapy
  • Antibody therapeutics
  • T-cell receptor profiling
  • TBI initiatives in cancer therapy
  • Cancer research
  • Kickstart your cancer research with long-read sequencing
  • Sample prep from FFPE tissue
  • Sample prep from plasma
  • Cancer biomarker quantification
  • Single cancer cell analysis
  • Cancer transcriptome analysis
  • Cancer genomics and epigenomics
  • HLA typing in cancer
  • Gene editing for cancer therapy/drug discovery
  • Alzheimer's disease research
  • Antibody engineering
  • Sample prep from FFPE tissue
  • Single-cell sequencing
  • Reproductive health technologies
  • Embgenix FAQs
  • Preimplantation genetic testing
  • ESM partnership program
  • ESM Collection Kit forms
  • Infectious diseases
  • Develop vaccines for HIV
  • About
  • BioView blog
  • That's Good Science!
  • Our brands
  • Our history
  • In the news
  • Events
  • Careers
  • Trademarks
  • License statements
  • Quality and compliance
  • HQ-grade reagents
  • International Contacts by Region
  • Need help?
  • Website FAQs
  • BioView blog
  • Automation
  • Cancer research
  • Career spotlights
  • Current events
  • Customer stories
  • Gene editing
  • Research news
  • Single-cell analysis
  • Stem cell research
  • Tips and troubleshooting
  • Women in STEM
  • That's Good Support!
  • About our blog
  • That's Good Science!
  • SMART-Seq Pro Biomarker Discovery Contest
  • DNA extraction educational activity
  • That's Good Science Podcast
  • Season one
  • Season two
  • Season three
  • Events
  • Biomarker discovery events
  • Calendar
  • Conferences
  • Speak with us
  • Careers
  • Company benefits
  • International Contacts by Region
  • United States and Canada
  • China
  • Japan
  • Korea
  • Europe
  • India
  • Affiliates & distributors
  • Need help?
  • Privacy request
Takara Bio
  • Products
  • Services & Support
  • Learning centers
  • APPLICATIONS
  • About
  • Contact Us